Nebiscon (Nebivolol Hydrochloride)

Nebivolol blocks β1‑adrenergic receptors in the heart, reducing heart rate and contractile force. In addition, it enhances nitric oxide release from the endothelium, causing vasodilation. The combined effect decreases peripheral vascular resistance and lowers systemic blood pressure.

The dose of Nebiscon is individualized by the prescribing clinician based on the patient’s clinical condition, response, and tolerability. Dosage adjustments may be needed for renal or hepatic impairment, and the prescriber determines the appropriate regimen.

Safety of nebivolol in pregnancy and lactation has not been established. It should be avoided unless the potential benefit justifies the potential risk to the fetus or infant, and the decision should be made by a qualified healthcare professional.

To request Nebiscon, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and necessary import documentation.

Nebivolol is a highly selective β1‑blocker with additional nitric‑oxide‑mediated vasodilation, which may result in fewer metabolic side effects compared with non‑selective beta blockers. Its dual mechanism can provide better blood‑pressure control while preserving endothelial function.

Nebiscon should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the product from moisture, excessive heat and direct sunlight to maintain its stability throughout its shelf life.

Nebiscon is taken orally, usually once daily, with or without food as directed by the prescriber. Swallow the tablet whole with a glass of water; do not crush or chew unless specifically instructed.

Serious risks include severe bradycardia, marked hypotension, heart block, and rare allergic reactions such as angioedema. Patients should be monitored for these events, especially during dose initiation or when combined with other cardiovascular drugs.

Nebiscon is contraindicated in patients with known hypersensitivity to nebivolol or any component of the formulation, in those with severe bradycardia, second‑ or third‑degree AV block without a pacemaker, and in patients with uncompensated heart failure. Clinical judgment is required for other special populations.